Literature DB >> 24862128

Microenvironment and multiple myeloma spread.

Domenico Ribatti1, Michele Moschetta2, Angelo Vacca3.   

Abstract

In patients with multiple myeloma (MM), the bone marrow (BM) contains hematopoietic stem cells (HSCs) and non-hematopoietic cells. HSCs are able to give rise to all types of mature blood cells, while the non hematopoietic component includes mesenchymal stem cells (MSCs), fibroblasts, osteoblasts, osteoclasts, chondroclasts, endothelial cells, endothelial progenitor cells (EPCs), B and T lymphocytes, NK cells, erythrocytes, megakaryocytes, platelets, macrophages and mast cells. All of these cells form specialized "niches" in the BM microenvironment which are close to the vasculature ("vascular niche") or to the endosteum ("osteoblast niche"). The "vascular niche" is rich in blood vessels where endothelial cells and mural cells (pericytes and smooth muscle cells) create a microenvironment that affects the behavior of several stem and progenitor cells. The vessel wall serves as an independent niche for the recruitment of endothelial progenitor cells, MSCs and HSCs. The activation by angiogenic factors and inflammatory cytokines switch the "vascular niche" to promote MM tumor growth and spread. This review will focus on the mechanisms involved in the generation of signals released by endothelial cells in the "vascular niche" that promote tumor growth and spread in MM.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Endothelial cells; Multiple myeloma; Tumor microenvironment

Mesh:

Year:  2014        PMID: 24862128     DOI: 10.1016/S0049-3848(14)50017-5

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  19 in total

1.  Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma.

Authors:  S Panchabhai; K Kelemen; G Ahmann; S Sebastian; J Mantei; R Fonseca
Journal:  Leukemia       Date:  2015-07-23       Impact factor: 11.528

Review 2.  Evolutionary biology of high-risk multiple myeloma.

Authors:  Charlotte Pawlyn; Gareth J Morgan
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

Review 3.  CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies.

Authors:  Jian-Qing Mi; Jie Xu; Jianfeng Zhou; Weili Zhao; Zhu Chen; J Joseph Melenhorst; Saijuan Chen
Journal:  Front Med       Date:  2021-12-18       Impact factor: 4.592

4.  Correlation between CD117+ myeloma plasma cells and hematopoietic progenitor cells in different categories of patients.

Authors:  Fanny Pojero; Alessandra Casuccio; Francesco Di Bassiano; Francesco Gervasi; Giuseppina Colonna Romano; Calogero Caruso
Journal:  Immun Ageing       Date:  2015-06-04       Impact factor: 6.400

Review 5.  B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?

Authors:  P J Hengeveld; M J Kersten
Journal:  Blood Cancer J       Date:  2015-02-27       Impact factor: 11.037

6.  Clinicopathological significance of p15 promoter hypermethylation in multiple myeloma: a meta-analysis.

Authors:  Bing Wei; Shuhua Yang; Bo Zhang; Yong Feng
Journal:  Onco Targets Ther       Date:  2016-07-01       Impact factor: 4.147

7.  NK cells and multiple myeloma-associated endothelial cells: molecular interactions and influence of IL-27.

Authors:  Alessandra Dondero; Beatrice Casu; Francesca Bellora; Angelo Vacca; Annunziata De Luisi; Maria Antonia Frassanito; Claudia Cantoni; Silvia Gaggero; Daniel Olive; Alessandro Moretta; Cristina Bottino; Roberta Castriconi
Journal:  Oncotarget       Date:  2017-05-23

8.  Systemic modeling myeloma-osteoclast interactions under normoxic/hypoxic condition using a novel computational approach.

Authors:  Zhiwei Ji; Dan Wu; Weiling Zhao; Huiming Peng; Shengjie Zhao; Deshuang Huang; Xiaobo Zhou
Journal:  Sci Rep       Date:  2015-08-18       Impact factor: 4.379

Review 9.  Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.

Authors:  Jinheng Wang; Sylvia Faict; Ken Maes; Elke De Bruyne; Els Van Valckenborgh; Rik Schots; Karin Vanderkerken; Eline Menu
Journal:  Oncotarget       Date:  2016-06-21

10.  Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes.

Authors:  P Hari; M-V Mateos; R Abonour; S Knop; W Bensinger; H Ludwig; K Song; R Hajek; P Moreau; D S Siegel; S Feng; M Obreja; S K Aggarwal; K Iskander; H Goldschmidt
Journal:  Leukemia       Date:  2017-04-25       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.